MODIFIED PEPTIDE ANTAGONISTS OF INTERLEUKIN 5 EXHIBIT EXTENDED IN VIVO PERSISTENCE BUT RESTRICTED SPECIES SPECIFICITY
- 31 July 2001
- Vol. 15 (1) , 10-19
- https://doi.org/10.1006/cyto.2001.0886
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Unambiguous synthesis of stromal cell-derived factor-1 by regioselective disulfide bond formation using a DMSO–aqueous HCl systemChemical Communications, 1998
- The role of the eosinophil-selective chemokine, eotaxin, in allergic and non-allergic airways inflammationMemórias do Instituto Oswaldo Cruz, 1997
- A rapid activation assay for human eosinophils based on adhesion to immobilized ICAM-1, VCAM-1 and IgGCytokine, 1996
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.The Journal of Experimental Medicine, 1996
- TNFα‐induced activation of eosinophil oxidative metabolism and morphology ‐ Comparison with IL‐5*Experimental Dermatology, 1994
- Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part II)European Respiratory Journal, 1994
- Effect of murine recombinant interleukin-5 on bronchial reactivity in guinea-pigsClinical and Experimental Allergy, 1993
- AsthmaNew England Journal of Medicine, 1992
- Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applicationsJournal of the American Chemical Society, 1991
- Light-scattering polarization measurements as a new parameter in flow cytometryCytometry, 1987